| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health |
| Completed | N/A | 42 | US | Rifaximin, placebo | Hunter Holmes Mcguire Veteran Affairs Medical Center, Bausch Health Americas, Inc. | Hepatic Encephalopathy | 04/10 | 05/10 | | |
NCT01218568: Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial |
|
|
| Completed | N/A | 120 | RoW | Rifaximin plus lactulose, Lactulose | Institute of Liver and Biliary Sciences, India | Hepatic Encephalopathy | 09/12 | 10/12 | | |
NCT02163837: Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy |
|
|
| Completed | N/A | 15 | Europe | rifaximine, Targaxan | Centre Hospitalier Universitaire Saint Pierre | Hepatic Encephalopathy | 07/15 | 07/15 | | |
NCT01773538: Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement |
|
|
| Completed | N/A | 136 | Europe | Lactulose and rifaximin, Branched Chain amino acids, Placebo | Mette Munk Lauridsen, Region of Southern Denmark, Odense University Hospital, Hospital of South West Jutland | Liver Cirrhosis, Hepatic Encephalopathy | 10/15 | 11/15 | | |
NCT02321371: Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy. |
|
|
| Completed | N/A | 73 | RoW | Lactulose + Rifaximin, Lactulose | Institute of Liver and Biliary Sciences, India | Acute-On-Chronic Liver Failure | 01/16 | 01/16 | | |
NCT01846806: The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. |
|
|
| Terminated | N/A | 10 | US | Rifaximin | NYU Langone Health, Bausch Health Americas, Inc. | Hepatic Encephalopathy | 03/16 | 03/16 | | |
PROSPER, NCT02488993: Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin |
|
|
| Completed | N/A | 389 | Europe | Prospective Phase Rifaximin-α 550mg, TARGAXAN, XIFAXAN, Prospective Phase No Rifaximin-α 550mg, Retrospective Phase | Norgine | Hepatic Encephalopathy | 09/18 | 09/18 | | |
NCT04077125: Transcranial Doppler Ultrasound and Minimal Hepatic Encephalopathy |
|
|
| Completed | N/A | 100 | Europe | Rifaximin | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Minimal Hepatic Encephalopathy | 12/18 | 03/19 | | |
NCT03115697: High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit. |
|
|
| Withdrawn | N/A | 0 | RoW | Lactulose, Rifaximin, Plasmapheresis | Institute of Liver and Biliary Sciences, India | Refractory Hepatic Encephalopathy | 04/19 | 04/19 | | |
NCT04787276: Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy |
|
|
| Completed | N/A | 42 | NA | E.coli Nissle 1917, MUTAFLOR capsules, Lactulose, DUPHALAC, Rifaximin, Alfa Normix | Bogomolets National Medical University | Hepatic Encephalopathy, Liver Cirrhosis, End Stage Liver DIsease | 01/20 | 03/20 | | |
NCT02439307: Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial |
|
|
| Terminated | N/A | 11 | RoW | Rifaximin, Antibiotic, Placebo, Action lacks substance | Coordinación de Investigación en Salud, Mexico | Small Intestinal Bacterial Overgrowth, Liver Cirrhosis | 07/21 | 07/21 | | |
ChiCTR2000040960: Comparison of probiotics and rifaximin in the prevention and treatment of minimal hepatic encephalopathy and their effects on intestinal flora in patients with liver cirrhosis |
|
|
| Recruiting | N/A | 60 | | 3 bid capsules of Bifidobacterium Triple Live bacteria ;Rifaximin0.6g, bid ;Lactulose (Adjust freely according to the number of stools) | Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University; Level of the institution：, The science and technology Department of Anhui Province | minimal hepatic encephalopathy | | | | |
